Milk thistle derivative demonstrates efficacy in non alcoholic liver disease

An ingredient derived from the milk thistle plant is shaping up to be a useful treatment option for non-alcoholic liver disease, new research shows. Results from the double-blind, placebo-controlled study of silymarin have shown that this herbal remedy shows a significantly higher percentage of the non-alcoholic steatohepatitis (NASH) patients experienced a resolving of their disease after 48 weeks of treatment with silymarin, compared to those on placebo.

To continue reading this article, please Log In or Sign Up for access.